LENSAR applies for CE Mark certification of ALLY System in European Union

LENSAR, Inc.

Application for CE Mark certification of the ALLY Adaptive Cataract Treatment System submitted.
CE Mark would allow commercialization of ALLY in the European Union following successful certification.
Application follows U.S. FDA clearance of ALLY in June 2022 and the U.S. commercial launch.
Company plans to use distributor network for EU commercialization, similar to first-generation system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.